Chapter 5. Microarray-Based Comparative Genomic Hybridization

  1. Mary Hannon-Fletcher Lecturer2 and
  2. Perry Maxwell Principal Clinical Scientist3
  1. David S. P. Tan,
  2. Rachael Natrajan and
  3. Jorge S. Reis-Filho

Published Online: 11 MAY 2009

DOI: 10.1002/9780470745069.ch5

Advanced Techniques in Diagnostic Cellular Pathology

Advanced Techniques in Diagnostic Cellular Pathology

How to Cite

Tan, D. S. P., Natrajan, R. and Reis-Filho, J. S. (2009) Microarray-Based Comparative Genomic Hybridization, in Advanced Techniques in Diagnostic Cellular Pathology (eds M. Hannon-Fletcher and P. Maxwell), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470745069.ch5

Editor Information

  1. 2

    The University of Ulster, Coleraine, UK

  2. 3

    Belfast Health & Social Care Trust, Centre for Cancer Research & Cell Biology, Belfast, UK

Author Information

  1. Molecular Pathology, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK

Publication History

  1. Published Online: 11 MAY 2009
  2. Published Print: 17 APR 2009

ISBN Information

Print ISBN: 9780470515976

Online ISBN: 9780470745069

SEARCH

Keywords:

  • microarray-based comparative genomic hybridization;
  • targeted therapy - rational design and therapeutic agent development;
  • oncogenes and tumour-suppressor genes - cell proliferation and cell fate determination;
  • microarray-based comparative genomic hybridization (aCGH) technologies;
  • array CGH is - based on same principles as metaphase CGH;
  • bacterial artificial chromosomes (BACs), P1-derived artificial chromosomes (PACs) and yeast artificial chromosomes (YACs) - large insert genomic clones aCGH studies;
  • molecular inversion probes (MIPs) - single oligonucleotides with two flanking inverted recognition sequences;
  • data integration and genomic data integration;
  • identification of novel amplicons and tumour-suppressor genes by aCGH - step forward in unravelling cancer complexity;
  • understanding complexity of cancers at genomic and transcriptomic level - step towards goal of individualized medicine

Summary

Microarray-based comparative genomic hybridization (aCGH) is contributing to the molecular characterisation of solid malignancies. This technique provides tremendous opportunities for translational research by facilitating detailed analysis of entire cancer genomes in a single experiment with unprecedented resolution. Apart from providing data to help catalogue the molecular genetic profiles of breast cancers and breast cancer cell lines, aCGH has also proven to be a useful technique for the identification of novel therapeutic targets. However, aCGH alone does not provide all lines of evidence required for the identification of ‘amplicon drivers’ and ‘druggable targets’. This can be more effectively achieved by integrating data from aCGH, expression profiling and RNA interference experiments. In this review, we discuss the techniques available for aCGH analysis and possible approaches for using aCGH as a tool for the identification of novel therapeutic targets.